来法莫林:治疗社区获得性细菌性肺炎的新型口服与静脉用截短侧耳素
来法莫林是一种新型半合成截短侧耳素类抗菌药,通过结合细菌50S核糖体亚基肽基转移酶中心抑制蛋白合成,对常见CABP病原体有广谱活性。药代动力学显示口服生物利用度空腹24%、餐后19%,III期LEAP 1和LEAP 2试验证实其口服和静脉制剂治疗CABP非劣效于莫西沙星。FDA、EMA和加拿大卫生部均已批准其用于CABP。
要点
- 来法莫林对革兰阳性、阴性需氧及厌氧菌与非典型病原体有广谱活性,耐药率低且无交叉耐药。
- 口服生物利用度空腹24%、餐后19%,600mg单剂空腹Cmax 1.2-1.5mg/L,t1/2 6.9-13.2h。
- LEAP 1和LEAP 2试验证实口服和静脉来法莫林治疗CABP非劣效于莫西沙星。
核心结论
- 来法莫林是治疗CABP的安全有效选择,尤其适用于一线治疗耐药、临床失败或对现有药物不耐受/不良反应的病例。
研究设计与样本
- 综述了来法莫林的化学结构、作用机制、抗菌谱、药代动力学、药效学、动物模型及II期ABSSSI和III期CABP临床试验。
主要发现
- 来法莫林通过结合50S核糖体亚基肽基转移酶中心抑制细菌蛋白合成,诱导契合机制使结合口袋旋转运动收紧。
- 药代动力学:分布容积82.9-202.8L,总清除率19.5-21.4L/h,终末半衰期6.9-13.2h。
- 口服600mg单剂空腹Cmax 1.2-1.5mg/L,Tmax 0.8-1.8h,AUC0-∞ 8.5-8.8mg·h/L。
- 预测疗效的药效学参数为fAUC24h/MIC。
- LEAP 1和LEAP 2试验确立口服和静脉来法莫林治疗CABP非劣效于莫西沙星。
关键数值与推荐
- 口服生物利用度空腹24%、餐后19%。
- 蛋白结合率高且呈非线性。
- 常见不良反应为轻中度胃肠道事件如恶心和腹泻。
临床怎么用
- 来法莫林可用于CABP治疗,尤其一线治疗耐药、临床失败或对现有药物不耐受/不良反应时。
- 临床经验和持续研究将帮助临床医生和抗菌药物管理项目优化来法莫林在CABP中的使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lefamulin is a novel oral and intravenous (IV) pleuromutilin developed as a twice-daily treatment for community-acquired bacterial pneumonia (CABP). It is a semi-synthetic pleuromutilin with a chemical structure that contains a tricyclic core of five-, six-, and eight-membered rings and a 2-(4-amino-2-hydroxycyclohexyl)sulfanylacetate side chain extending from C14 of the tricyclic core. Lefamulin inhibits bacterial protein synthesis by binding to the 50S bacterial ribosomal subunit in the peptidyl transferase center (PTC). The pleuromutilin tricyclic core binds to a pocket close to the A site, while the C14 side chain extends to the P site causing a tightening of the rotational movement in the binding pocket referred to as an induced-fit mechanism. Lefamulin displays broad-spectrum antibacterial activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria as well as against atypical bacteria that commonly cause CABP. Pleuromutilin antibiotics exhibit low rates of resistance development and lack cross-resistance to other antimicrobial classes due to their unique mechanism of action. However, pleuromutilin activity is affected by mutations in 23S rRNA, 50S ribosomal subunit proteins rplC and rplD, ATP-binding cassette (ABC)-F transporter proteins such as vga(A), and the methyltransferase cfr. The pharmacokinetic properties of lefamulin include: volume of distribution (Vd) ranging from 82.9 to 202.8 L, total clearance (CLT) of 19.5 to 21.4 L/h, and terminal elimination half-life (t1/2) of 6.9-13.2 h; protein binding of lefamulin is high and non-linear. The oral bioavailability of lefamulin has been estimated as 24% in fasted subjects and 19% in fed subjects. A single oral dose of lefamulin 600 mg administered in fasted patients achieved a maximum plasma concentration (Cmax) of 1.2-1.5 mg/L with a time of maximum concentration (Tmax) ranging from 0.8 to 1.8 h, and an area under the plasma concentration-time curve from 0 to infinity (AUC0-∞) of 8.5-8.8 mg h/L. The pharmacodynamic parameter predictive of lefamulin efficacy is the free plasma area under the concentration-time curve divided by the minimum inhibitory concentration (fAUC24h/MIC). Lefamulin efficacy has been demonstrated using various animal models including neutropenic murine thigh infection, pneumonia, lung infection, and bacteremia. Lefamulin clinical safety and efficacy was investigated through a Phase II clinical trial of acute bacterial skin and skin structure infection (ABSSSI), as well as two Phase III clinical trials of CABP. The Phase III trials, LEAP 1 and LEAP 2 established non-inferiority of lefamulin to moxifloxacin in both oral and IV formulations in the treatment of CABP. The United States Food and Drug Administration (FDA), European Medicines Agency (EMA), and Health Canada have each approved lefamulin for the treatment of CABP. A Phase II clinical trial has been completed for the treatment of ABSSSI, while the pediatric program is in Phase I. The most common adverse effects of lefamulin include mild-to-moderate gastrointestinal-related events such as nausea and diarrhea. Lefamulin represents a safe and effective option for treating CABP in cases of antimicrobial resistance to first-line therapies, clinical failure, or intolerance/adverse effects to currently used agents. Clinical experience and ongoing clinical investigation will allow clinicians and antimicrobial stewardship programs to optimally use lefamulin in the treatment of CABP.
引用
- Zhanel GG, Deng C, Zelenitsky S, et al. Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia. Drugs. 2021. PMID: 33247830. doi:10.1007/s40265-020-01443-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。